Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost Implications

Autologous hematopoietic cell transplant (auto-HCT) is a mainstay treatment for hematologic malignancies such as multiple myeloma and lymphomas. Peripheral blood hematopoietic progenitor cells (PB-HPC) offer a faster hematopoietic recovery than HPC from bone marrow, making it the most common source of cells for auto-HCTs [1,2]. Three general approaches to mobilize PB-HPC are available: myeloid growth factors with or without the CXCR4 antagonist, plerixafor, and chemotherapy plus growth factors. Chemotherapy mobilization has been shown to produce similar failure rates with increased cost and toxicity compared to myeloid growth factor alone [3-8].

Source: Biology of Blood and Marrow Transplantation - September 13, 2018 Category: Hematology Authors: Nicole L Watts, Marisa B. Marques, Daniel B Peavey, Racquel Innis-Shelton, Ayman Saad, Antonio Di Stasi, Donna Salzman, Lawrence S Lamb, Luciano J Costa Source Type: research